Arrhythmia Detection After Myocardial Infarction Trial

What this Trial Is About

Researchers are evaluating the impact of implantable cardiac monitors (ICM) on managing patients after an acute myocardial infarction (AMI) to potentially improve their outcomes. Patients who experience ventricular tachycardia or fibrillation after AMI have a higher risk of sudden cardiac death, but current guidelines delay implantable cardioverter defibrillator (ICD) placement for at least 40 days post-AMI, leaving some patients unprotected during this vulnerable period. Previous studies have shown mixed results regarding timing and benefits of ICD placement, highlighting the need for better monitoring to guide treatment decisions. This trial compares two groups of post-AMI patients: one receiving standard care with routine clinic visits, and the other receiving standard care plus ICM implantation through a small skin incision within 21 days of their AMI. The ICM allows continuous remote monitoring of heart rhythms to detect arrhythmias that may require intervention. The study is randomized and single-blinded, aiming to assess how ICM use changes patient management and the timing of diagnosis or treatment of cardiac arrhythmias. Participants will be followed for up to 24 months, with primary outcomes measured at 90 days, including changes in patient management and time to arrhythmia diagnosis or treatment. Secondary outcomes include mortality at 90 days and 24 months, as well as longer-term management changes. Researchers will use remote monitoring data, clinical assessments, and hospital records to evaluate the effects of ICM on care decisions and patient survival after AMI.

Arrhythmia Detection After MI